JULY 23, 2026
FDA Advisory Panel Begins Two-Day Review of Seven Peptide Compounds Sought by Compounding Pharmacies
A Food and Drug Administration advisory panel began a two-day meeting on July 23, 2026 to vote on recommendations for seven peptide compounds — including BPC-157, TB-500 and MOTs-C — that could become available through compounding pharmacies. None of the seven compounds has undergone large-scale clinical trials required for standard FDA drug approval. FDA scientists have recommended against giving compounding pharmacies the go-ahead to produce any of the seven peptides, citing data derived primarily from animal studies with limited human evidence.
A Food and Drug Administration advisory committee convened Thursday to begin evaluating evidence for seven peptide therapies, opening a process that will span two days and involve votes on each compound individually. The panel's recommendations are advisory; FDA leadership retains final authority over whether to reclassify any of the substances for compounding pharmacy production.
The seven compounds under review — BPC-157, KPV, TB-500, MOTs-C, Emideltide, Epitalon and Semax — have drawn significant interest in wellness and sports-recovery communities, where they are promoted for uses including injury recovery, muscle growth, fat loss, skin health and metabolic enhancement, according to NPR. Peptides are strings of amino acids, smaller than proteins, that act as signaling molecules in the body; BPC-157 is derived from a peptide found in human stomach juices, while TB-500 is related to a molecule called thymosin beta-4 found in many cell types.
FDA scientists, in their pre-meeting review, noted that evidence for the compounds comes primarily from preclinical animal work and is limited for humans — the basis for their recommendation against approving compounding pharmacy access to any of the seven. The committee was tasked with reviewing data supporting use in specific conditions including migraines, ulcerative colitis, opioid withdrawal and wound healing; however, NPR reported that if FDA ultimately reclassifies the compounds, clinicians would retain discretion to prescribe them outside those narrow indications.